US FDA approves Regeneron's blood cancer therapy
Shares of the company rose 2% following the approval.
The company said it is "working diligently" to make the therapy, branded Lynozyfic, commercially available as quickly as possible, and has set a wholesale acquisition cost of $470 per 5 mg vial and $18,800 per 200 mg vial.
The accelerated approval was based on a mid-stage trial, in which 70% of patients on Lynozyfic saw their cancer shrink or disappear, while 45% achieved a complete disappearance of their cancer.
Lynozyfic is a type of drug called monoclonal antibody that works by targeting two proteins - one found on myeloma cells known as BCMA and another one found on immune T-cells called CD3.
These so-called "bispecific antibodies" are "paradigm shifting," Andres Sirulnik, Regeneron's clinical development head for hematology, said. Regeneron is exploring moving such drugs to earlier lines of therapy as they can replace many of the existing treatments used as a standard of care, Sirulnik added.
Other bispecific antibodies approved for multiple myeloma are Johnson & Johnson's Tecvayli and Pfizer's Elrexfio. Like Elrexfio and Tecvayli, Lynozyfic comes with a boxed warning for neurologic toxicity and cytokine release syndrome, a condition where the immune system reacts more aggressively.
Over 36,000 new cases of multiple myeloma are estimated to be diagnosed in the U.S. in 2025, according to the American Cancer Society. Regeneron estimates about 4,000 new cases will be among those who have received four or more lines of treatment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
5 days ago
- The Hindu
US FDA approves Regeneron's blood cancer therapy
Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood cancer called multiple myeloma that has recurred in patients who had received at least four other therapies earlier. Shares of the company rose 2% following the approval. The company said it is "working diligently" to make the therapy, branded Lynozyfic, commercially available as quickly as possible, and has set a wholesale acquisition cost of $470 per 5 mg vial and $18,800 per 200 mg vial. The accelerated approval was based on a mid-stage trial, in which 70% of patients on Lynozyfic saw their cancer shrink or disappear, while 45% achieved a complete disappearance of their cancer. Lynozyfic is a type of drug called monoclonal antibody that works by targeting two proteins - one found on myeloma cells known as BCMA and another one found on immune T-cells called CD3. These so-called "bispecific antibodies" are "paradigm shifting," Andres Sirulnik, Regeneron's clinical development head for hematology, said. Regeneron is exploring moving such drugs to earlier lines of therapy as they can replace many of the existing treatments used as a standard of care, Sirulnik added. Other bispecific antibodies approved for multiple myeloma are Johnson & Johnson's Tecvayli and Pfizer's Elrexfio. Like Elrexfio and Tecvayli, Lynozyfic comes with a boxed warning for neurologic toxicity and cytokine release syndrome, a condition where the immune system reacts more aggressively. Over 36,000 new cases of multiple myeloma are estimated to be diagnosed in the U.S. in 2025, according to the American Cancer Society. Regeneron estimates about 4,000 new cases will be among those who have received four or more lines of treatment.
Mint
5 days ago
- Mint
Listeria risk outbreak: FDA sounds alarm, recalls tainted blueberries
The U.S. Food and Drug Administration (FDA) has issued its most serious warning for contaminated organic blueberries. Alma Pak International recalled 400 boxes (12,000 pounds) of berries after routine tests found Listeria monocytogenes, a deadly bacteria. The Georgia-based company shipped the tainted fruit to one customer in North Carolina before catching the problem in June. By July 1, the FDA declared this a "Class I recall" – meaning eating these berries could cause severe sickness or death. The risky blueberries carry lot numbers 13325 G1060 and 13325 G1096. Though the company claims no berries reached grocery stores, the FDA warns everyone to check their freezers and avoid these products completely. Listeria isn't just ordinary food poisoning. It's America's third-deadliest foodborne illness, killing about 260 people yearly. Unlike most bacteria, Listeria grows in refrigerators, making it extra sneaky. Healthy adults might suffer only fever, vomiting, or diarrhea for a few days. But for pregnant women, it can trigger miscarriages or stillbirths. Older adults, newborns, and people with weak immune systems can develop deadly meningitis (brain swelling) or sepsis. Warning signs include intense headaches, stiff necks, confusion, or seizures. If you ate these berries and feel ill, doctors urge immediate medical help, especially if pregnant. This recall comes just weeks after listeria-tainted chicken meals caused 3 deaths and a miscarriage nationwide. This blueberry alert fits a frightening pattern: US food recalls are skyrocketing. In 2024 alone, roughly 300 recalls made 1,400 people sick, hospitalized 487, and killed 19, double 2023's death toll. Recent months saw recalls for shrimp, turkey, and prepared meals like FreshRealm's fettuccine (sold at Kroger and Walmart). While blueberries normally offer health benefits like better blood pressure and reduced inflammation, contaminated ones become dangerous. Experts advise washing produce thoroughly, cleaning fridge surfaces monthly, and monitoring FDA recall updates. As one microbiologist notes: 'Listeria's early symptoms look like regular flu, but delaying treatment can be fatal when it attacks your brain.'
Time of India
6 days ago
- Time of India
FDA issues highest-level recall for Alma Pak organic blueberries over Listeria contamination
The FDA has issued a Class I recall for Alma Pak International LLC's organic blueberries after Listeria monocytogenes was detected. This recall affects 400 boxes distributed to North Carolina. Listeria infection poses a severe risk, especially to vulnerable populations, potentially leading to serious illness or death. Consumers are urged to check lot numbers and seek medical attention if symptoms arise. Tired of too many ads? Remove Ads What's affected? Product: Organic blueberries from Alma Pak International LLC (Georgia-based) Quantity: 400 boxes, each weighing 30 pounds (totaling 12,000 pounds) Lot Numbers: 13325 G1060 and 13325 G1096 Distribution: Shipped to a single customer in North Carolina Why the urgency? Check their blueberries for the affected lot numbers Avoid consuming any recalled product Contact the retailer for a refund Seek medical attention if symptoms of listeriosis develop after consumption Company response and background Tired of too many ads? Remove Ads The U.S. Food and Drug Administration (FDA) has issued a Class I recall—the highest possible risk level—for 400 boxes of organic blueberries distributed by Alma Pak International LLC, following the detection of Listeria monocytogenes during routine testing. The recall, first initiated on June 9, 2025, was elevated to Class I status on July 1, signaling a 'reasonable probability' that consuming the affected product could lead to serious health consequences or even death, according to the FDA's official monocytogenes is a dangerous bacteria that can contaminate various foods. Infection, known as listeriosis, is particularly hazardous for newborns, adults over 65, and individuals with weakened immune systems. Symptoms range from fever, muscle aches, nausea, vomiting, and diarrhea in milder cases, to severe complications such as headaches, neck stiffness, confusion, loss of coordination, and seizures in more vulnerable individuals. Listeria infection is the third leading cause of death from foodborne illness in the U.S., causing around 260 deaths are urged to:The FDA's Class I recall status underscores the seriousness of this contamination, as the agency warns that exposure to the tainted blueberries could result in life-threatening Pak International LLC has voluntarily recalled the product and is cooperating with authorities. Notably, this is not the company's first recall—previous incidents have included recalls for other frozen berry products due to contamination recall comes amid a broader trend of increased food recalls in 2024 and 2025, with a notable rise in hospitalizations and deaths linked to foodborne you have purchased Alma Pak organic blueberries, check your packaging immediately and follow FDA guidance to ensure your safety.
